Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340697 | 0.80 | SNCA (0.46) | SNCAKCNH2ERN1LTA4HHDAC1 | |
| SCHEMBL196515 | 0.75 | LTA4H (0.52) | SNCANPC1RAB9ALTA4HHDAC1 | |
| SCHEMBL4755025 | 0.75 | RAB9A (0.35) | ADORA1NPC1RAB9AATMLTA4H | |
| SCHEMBL8508787 | 0.74 | MEN1 (0.36) | SNCAKCNH2NPC1RAB9AATM | |
| SCHEMBL498603 | 0.74 | DPP4 (0.53) | SNCANPC1RAB9ALTA4HHDAC1 | |
| SCHEMBL1780394 | 0.72 | HDAC1 (0.36) | SNCAADORA1NPC1RAB9AATM | |
| SCHEMBL27887927 | 0.71 | SNCA (0.53) | SNCAPGRNPC1RAB9AATM | |
| SCHEMBL13656725 | 0.71 | SNCA (0.49) | SNCAPGRNPC1RAB9AATM | |
| SCHEMBL15446989 | 0.70 | DPP4 (0.40) | NPC1RAB9AATMLTA4HHDAC1 | |
| SCHEMBL14190039 | 0.69 | LTA4H (0.48) | NPC1RAB9AATMLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531619-B2 | Process for producing dendrimer, building block compound, and process for producing thiophene compound | TOYO GOSEI CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1535942-B1 | METHOD FOR PRODUCING A ENDRIMER, BUILDING BLOCK COMPOUND, AND METHOD FOR PRODUCING A THIOPHENE COMPOUND | TOYO GOSEI CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-20060122364-A1 | Process for producing dendrimer, building block compound, and process for producing thiophene compound | TOYO GOSEI CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1535942-A1 | PROCESS FOR PRODUCING DENDRIMER, BUILDING BLOCK COMPOUND, AND PROCESS FOR PRODUCING THIOPHENE COMPOUND | Toyo Gosei Co., Ltd. (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122364-A1 | Process for producing dendrimer, building block compound, and process for producing thiophene compound | CCKBR, MVD, DRD4 | SNCA 1259/4885PGR 3444/4885KCNH2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.